Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wuzhi Drop Pills is a traditional Chinese medicine (TCM) preparation derived from the ethanol extract of *Schisandra sphenanthera*. It is officially approved in China for the treatment of elevated alanine aminotransferase (ALT) levels associated with chronic hepatitis and other forms of liver injury. The formulation contains dibenzocyclooctadiene lignans, such as schisandrin A, B, and C, which exhibit potent hepatoprotective and antioxidant properties. In clinical practice, Wuzhi Drop Pills is frequently utilized as an adjuvant therapy in organ transplant recipients. It acts as a significant inhibitor of the cytochrome P450 3A (CYP3A) enzyme system, which reduces the metabolism of immunosuppressants like tacrolimus and cyclosporine A, thereby increasing their blood concentrations and allowing for lower therapeutic dosing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Wuzhi Drop Pills.